IGC Pharma granted U.S. patent covering IGC-AD1

IGC Pharma (IGC) announced that the United States Patent and Trademark Office has granted the company U.S. Patent No. 12,465,589, titled “Methods and Composition for Treating CNS Disorders.” The patent covers the propriety formulation used in IGC-AD1, the Company’s lead drug candidate currently being evaluated in the Phase 2 CALMA trial for agitation in Alzheimer’s disease. The patent granted on November 11, 2025, covers a proprietary composition for treating Alzheimer’s disease including amyloid plaque, tau tangles as well as symptoms associated with Alzheimer’s, such as agitation, memory, cognition, anxiety, and sleep disturbances This patented composition is designed to reduce amyloid-beta expression and aggregation, enhance mitochondrial function, decrease phosphorylation of GSK3beta, and lower tau phosphorylation, thereby addressing both behavioral symptoms and core disease mechanisms of Alzheimer’s. Importantly, the combination seeks to achieve these effects without serious side effects, a critical advancement in the development of safer, more effective therapies for neurodegenerative diseases.